News Agency
Men's Weekly

CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

  • Written by PR Newswire

Key Highlights:

  • Excellent Safety Profile:  As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data continue to show a favorable safety profile, with 23% incidence of Grade ≥3 Treatment-Related Adverse...

Read more: CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific...

Understanding Your Rights Around Property After Separation

Property division is one of the most significant financial matters that arises when a relationship ends, and it's also one of the most commonly misunderstood. Many people assume that assets are simply divided equally, but the reality under Australian family... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion